Drug profile · INN
brexanolone
ZULRESSO
brexanolone (ZULRESSO) is a gaba-a receptor; anion channel positive allosteric modulator. Route of administration: intravenous. Current US regulatory status: approved.
Drug details — brexanolone
- US status
- approved
- Class
- —
- Route
- INTRAVENOUS
- Patents
- 1
- Programs
- 3
- Data quality
- 0.84
Quick answer
brexanolone (ZULRESSO) is a gaba-a receptor; anion channel positive allosteric modulator. Route of administration: intravenous. Current US regulatory status: approved.
Key facts
Mechanism of action
GABA-A receptor; anion channel positive allosteric modulator
Primary target: GABA-A receptor; anion channel
Approval history
| Authority | Status | Date |
|---|---|---|
| FDA | approved | — |
Pipeline programs
Related & competitor drugs
Related patents
Frequently asked questions
What is brexanolone?
brexanolone (ZULRESSO) is a gaba-a receptor; anion channel positive allosteric modulator. Route of administration: intravenous. Current US regulatory status: approved.
What is the brand name for brexanolone?
ZULRESSO is a marketed brand name for brexanolone. Check FDA Drugs@FDA for the current US label holder and prescribing information.
What is the US approval status of brexanolone?
brexanolone has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.